Perceptive Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Perceptive Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,150,641	Closed	-$14.4M	–	122
2022 Q3	$14.4M	Hold	2,150,641	–	–	0.42%	55
2022 Q2	$9.05M	Hold	2,150,641	–	–	0.28%	63
2022 Q1	$7.25M	Hold	2,150,641	–	–	0.15%	92
2021 Q4	$6.77M	Hold	2,150,641	–	–	0.1%	108
2021 Q3	$7.03M	Hold	2,150,641	–	–	0.1%	111
2021 Q2	$9.07M	Hold	2,150,641	–	–	0.12%	112
2021 Q1	$10.7M	Hold	2,150,641	–	–	0.14%	96
2020 Q4	$27.2M	Hold	2,150,641	–	–	0.29%	70
2020 Q3	$21.1M	Hold	2,150,641	–	–	0.31%	68
2020 Q2	$21.4M	Hold	2,150,641	–	–	0.35%	58
2020 Q1	$19.5M	Hold	2,150,641	–	–	0.51%	42
2019 Q4	$19.8M	Sell	2,150,641 -44,000	-2%	-$312K	0.39%	47
2019 Q3	$12.9M	Sell	2,194,641 -10,000	-0.5%	-$106K	0.35%	51
2019 Q2	$26.5M	Hold	2,204,641	–	–	0.61%	42
2019 Q1	$26.6M	Buy	2,204,641 +330,862	+18%	+$4.88M	0.75%	35
2018 Q4	$22.8M	Buy	+1,873,779	New	+$25.9M	0.87%	32
2015 Q4	–	Sell	-10,379	Closed	-$195K	–	182
2015 Q3	$195K	Buy	+10,379	New	+$176K	0.02%	134

Other funds holding CNCE

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors's CNCE Position: Q4 2022 in Review

Perceptive Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 2,150,641 shares — an estimated $14.4M sold.

Perceptive Advisors first reported a position in CNCE in Q3 2015 and held it in 17 quarters. The position peaked at $27.2M in Q4 2020. 84 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

Perceptive Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Perceptive Advisors sold 2,150,641 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $14.4M.
Perceptive Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 17 quarters.
Perceptive Advisors's Concert Pharmaceuticals, Inc. position peaked at $27.2M in Q4 2020.
84 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.